Carl E. Ruby

2.1k total citations
33 papers, 1.7k citations indexed

About

Carl E. Ruby is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Carl E. Ruby has authored 33 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Immunology, 10 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Carl E. Ruby's work include Immunotherapy and Immune Responses (16 papers), Immune Cell Function and Interaction (13 papers) and T-cell and B-cell Immunology (11 papers). Carl E. Ruby is often cited by papers focused on Immunotherapy and Immune Responses (16 papers), Immune Cell Function and Interaction (13 papers) and T-cell and B-cell Immunology (11 papers). Carl E. Ruby collaborates with scholars based in United States, Slovakia and Netherlands. Carl E. Ruby's co-authors include Andrew D. Weinberg, William L. Redmond, Howard L. Kaufman, Tasha M. Hughes, Craig L. Slingluff, Nancy I. Kerkvliet, Michael J. Gough, Birat Dhungel, Joseph R. Maxwell and Anthony T. Vella and has published in prestigious journals such as The Journal of Immunology, Cancer Research and Cell Host & Microbe.

In The Last Decade

Carl E. Ruby

33 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carl E. Ruby United States 22 1.0k 685 488 163 146 33 1.7k
Federica Pericle United States 27 1.2k 1.2× 595 0.9× 557 1.1× 272 1.7× 101 0.7× 42 1.9k
Walter C. Olson United States 28 1.4k 1.4× 896 1.3× 824 1.7× 132 0.8× 102 0.7× 56 2.0k
Michelle H. Nelson United States 19 713 0.7× 747 1.1× 604 1.2× 147 0.9× 123 0.8× 35 1.6k
Sandra Tuyaerts Belgium 25 1.5k 1.5× 917 1.3× 926 1.9× 243 1.5× 86 0.6× 55 2.1k
Juan Dubrot Spain 25 1.4k 1.4× 841 1.2× 525 1.1× 153 0.9× 100 0.7× 45 2.1k
Flavia Borellini United States 12 502 0.5× 556 0.8× 644 1.3× 276 1.7× 116 0.8× 23 1.3k
Jeff D. Colbert United States 18 944 0.9× 526 0.8× 804 1.6× 117 0.7× 240 1.6× 20 1.8k
Dori A. Thomas United States 9 1.2k 1.1× 885 1.3× 787 1.6× 100 0.6× 192 1.3× 9 2.0k
Marco Bestagno Italy 25 462 0.5× 552 0.8× 800 1.6× 115 0.7× 116 0.8× 51 1.9k
Cheryl Eppolito United States 16 1.2k 1.2× 1.1k 1.6× 273 0.6× 112 0.7× 59 0.4× 28 1.8k

Countries citing papers authored by Carl E. Ruby

Since Specialization
Citations

This map shows the geographic impact of Carl E. Ruby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl E. Ruby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl E. Ruby more than expected).

Fields of papers citing papers by Carl E. Ruby

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carl E. Ruby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl E. Ruby. The network helps show where Carl E. Ruby may publish in the future.

Co-authorship network of co-authors of Carl E. Ruby

This figure shows the co-authorship network connecting the top 25 collaborators of Carl E. Ruby. A scholar is included among the top collaborators of Carl E. Ruby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carl E. Ruby. Carl E. Ruby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ruby, Carl E., et al.. (2023). Potential Promises and Perils of Human Biological Treatments for Immunotherapy in Veterinary Oncology. Veterinary Sciences. 10(5). 336–336. 2 indexed citations
2.
Ruby, Carl E., Dan V. Mourich, Shay Bracha, et al.. (2022). Creating a Selective Nanobody Against 3-Nitrotyrosine Containing Proteins. Frontiers in Chemistry. 10. 835229–835229. 3 indexed citations
3.
Ramsey, Stephen A., et al.. (2021). Exosomal proteomic signatures correlate with drug resistance and carboplatin treatment outcome in a spontaneous model of canine osteosarcoma. Cancer Cell International. 21(1). 245–245. 20 indexed citations
4.
Troyer, Ryan M., Stephen A. Ramsey, Liping Yang, et al.. (2018). A Preliminary Proteomic Investigation of Circulating Exosomes and Discovery of Biomarkers Associated with the Progression of Osteosarcoma in a Clinical Model of Spontaneous Disease. Translational Oncology. 11(5). 1137–1146. 41 indexed citations
5.
Troyer, Ryan M., Carl E. Ruby, Cheri P. Goodall, et al.. (2017). Exosomes from Osteosarcoma and normal osteoblast differ in proteomic cargo and immunomodulatory effects on T cells. Experimental Cell Research. 358(2). 369–376. 64 indexed citations
6.
Turturro, Sanja, et al.. (2016). Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin. Breast Cancer Research and Treatment. 156(1). 33–43. 20 indexed citations
7.
Kohlhapp, Frederick J., Tasha M. Hughes, Erica Huelsmann, et al.. (2015). NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. Journal for ImmunoTherapy of Cancer. 3(1). 18–18. 45 indexed citations
8.
Wood, Stephen, et al.. (2015). Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines. Journal of Medical Microbiology. 64(Pt_2). 164–173. 29 indexed citations
9.
Kim, Dae Won, et al.. (2014). Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells. Journal of Translational Medicine. 12(1). 113–113. 19 indexed citations
10.
Kaufman, Howard L., Carl E. Ruby, Tasha M. Hughes, & Craig L. Slingluff. (2014). Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma. Journal for ImmunoTherapy of Cancer. 2(1). 11–11. 164 indexed citations
11.
Williamson, Ashley J., Lydia Usha, Geetha Rao, et al.. (2014). Inhibition of p70 S6 Kinase (S6K1) Activity by A77 1726 and Its Effect on Cell Proliferation and Cell Cycle Progress. Neoplasia. 16(10). 824–834. 28 indexed citations
12.
Goldufsky, Josef W., et al.. (2014). Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging. Cancer Immunology Immunotherapy. 63(6). 615–626. 31 indexed citations
13.
Kaufman, Howard L., Michael Pan, Sebastian Bernardo, et al.. (2013). Oncolytic virus therapy for cancer. PubMed. 2. 31–31. 52 indexed citations
14.
Vasilevsky, Nicole, Carl E. Ruby, Peter J. Hurlin, & Andrew D. Weinberg. (2011). OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen‐stimulated T cells leading to an increase in cell survival. European Journal of Immunology. 41(4). 1024–1034. 14 indexed citations
15.
Ruby, Carl E., Melissa A. Yates, Daniel Hirschhorn-Cymerman, et al.. (2009). Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right. The Journal of Immunology. 183(8). 4853–4857. 126 indexed citations
16.
Ruby, Carl E. & Andrew D. Weinberg. (2009). OX40-Enhanced Tumor Rejection and Effector T Cell Differentiation Decreases with Age. The Journal of Immunology. 182(3). 1481–1489. 35 indexed citations
17.
Gough, Michael J., et al.. (2008). OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor. Cancer Research. 68(13). 5206–5215. 139 indexed citations
18.
Maxwell, Joseph R., Rajwardhan Yadav, Robert J. Rossi, et al.. (2006). IL-18 Bridges Innate and Adaptive Immunity through IFN-γ and the CD134 Pathway. The Journal of Immunology. 177(1). 234–245. 82 indexed citations
19.
Ruby, Carl E., Castle Funatake, & Nancy I. Kerkvliet. (2005). 2,3,7,8 Tetrachlorodibenzo-p-Dioxin (TCDD) Directly Enhances the Maturation and Apoptosis of Dendritic CellsIn Vitro. Journal of Immunotoxicology. 1(3-4). 159–166. 23 indexed citations
20.
Maxwell, Joseph R., Carl E. Ruby, Nancy I. Kerkvliet, & Anthony T. Vella. (2002). Contrasting the Roles of Costimulation and the Natural Adjuvant Lipopolysaccharide During the Induction of T Cell Immunity. The Journal of Immunology. 168(9). 4372–4381. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Federica Pericle Breakdown of academic impact, for papers by Walter C. Olson Breakdown of academic impact, for papers by Michelle H. Nelson Breakdown of academic impact, for papers by Sandra Tuyaerts Breakdown of academic impact, for papers by Juan Dubrot Breakdown of academic impact, for papers by Flavia Borellini Breakdown of academic impact, for papers by Jeff D. Colbert Breakdown of academic impact, for papers by Dori A. Thomas Breakdown of academic impact, for papers by Marco Bestagno Breakdown of academic impact, for papers by Cheryl Eppolito
Rankless by CCL
2026